Recent Advances in Cancer Care — New Paradigms, Novel Agents and What It Means for the Oncology Nurse: Management of Pancreatic Cancer

Faculty

Program Schedule — Central Time

5:30 AM – 6:00 AM — Registration and Dinner
6:00 AM – 7:30 AM — Educational Meeting

MODULE 1: Clinical Presentation and Prognosis of Pancreatic Adenocarcinoma (PAD)

• Risk factors for the development of pancreatic cancer, such as family history/ genetic predisposition syndromes, smoking, obesity/diet and metabolic diseases
• Rationale for the high proportion of PAD cases diagnosed in the advanced stages of the disease
• Factors contributing to the aggressive nature of PAD; prognosis associated with advanced disease
• Common presenting symptoms of PAD, such as asthenia, anorexia/weight loss, pain and jaundice
• Importance of palliative care for patients with advanced PAD

MODULE 2: Recent Advances in Up-Front Treatment for Metastatic PAD

• Impact of age, performance status, comorbidities, patient preferences and prior (neo)adjuvant therapy, if any, on the choice of first-line treatment for metastatic PAD
• Historical data establishing the efficacy and safety of FOLFIRINOX and gemcitabine/nab paclitaxel for patients with previously untreated advanced PAD
• Proposed mechanism of improved delivery of cytotoxic therapy to pancreatic cancer cells with nanoliposomal irinotecan (nal-IRI) compared to conventional chemotherapy
• Key efficacy and safety outcomes reported with nal-IRI, fluorouracil (5-FU)/leucovorin (LV) and oxaliplatin (NALIRIFOX) versus gemcitabine/nab paclitaxel for previously untreated metastatic PAD
• FDA approval of up-front NALIRIFOX for patients with metastatic PAD; selection of optimal candidates for this regimen

MODULE 3: Selection and Sequencing of Therapy for Relapsed/Refractory (R/R) Metastatic PAD

• Key factors influencing the selection and sequencing of available therapies for R/R metastatic PAD
• Long-term efficacy and safety findings with nal-IRI in combination with 5-FU/LV after disease progression on gemcitabine-based therapy
• Patient selection for and practical integration of nal-IRI in the R/R setting
• Other evidence-based chemotherapeutic agents or regimens for patients with progressive metastatic PAD

MODULE 4: Tolerability and Other Practical Considerations with Nanoliposomal Irinotecan (Nal-IRI) and Other Cytotoxic Approaches

• Comparative tolerability/toxicity profile of NALIRIFOX and other commonly employed first-line regimens, such as FOLFIRINOX and gemcitabine/nab paclitaxel
• Rates of diarrhea and other gastrointestinal (GI) issues documented with nal-IRI; indications for prophylactic antidiarrheals and antiemetics for patients who are about to start treatment
• Incidence and severity of cytopenias with nal-IRI; role of growth factor use and appropriate monitoring of complete blood counts during therapy
• Recommended dosing of nal-IRI as part of the first-line NALIRIFOX regimen versus in the R/R setting
• Effect of dose adjustment on the efficacy of first-line NALIRIFOX; implications for the feasibility of tolerability-guided dosing strategies

MODULE 5: Novel Strategies Targeting RAS Mutations in Advanced PAD

• Incidence and spectrum of RAS mutations in PAD; impact on patient outcomes
• Mechanism of antitumor activity of the RAS(ON) multiselective inhibitor daraxonrasib and rationale for its investigation in advanced PAD
• Early efficacy outcomes with daraxonrasib as monotherapy and in combination with gemcitabine/nab paclitaxel for patients with previously treated and treatment-naïve advanced PAD harboring RAS mutations
• FDA breakthrough therapy designation for daraxonrasib for previously treated KRAS G12-mutant advanced PAD
• Ongoing and planned Phase III trials of daraxonrasib alone or in combination with chemotherapy for patients with PAD

MODULE 6: Tolerability of RAS-Targeted Therapies Under Investigation for Advanced PAD

• Incidence, time to onset and severity of GI side effects (eg, diarrhea, nausea, vomiting, stomatitis/mucositis, liver enzyme elevations) with daraxonrasib for patients with PAD
• Spectrum, incidence and severity of daraxonrasib-associated dermatologic issues, including rash, dry skin, paronychia and others
• Strategies to mitigate, monitor for and manage potential treatment-emergent adverse events (AEs) with daraxonrasib should it become available
• Impact on the tolerability of daraxonrasib when combined with chemotherapy

MODULE 7: Potential Utility of Tumor Treating Fields (TTFields) in the Management of PAD

• Mechanism of action of TTFields and biological rationale for their investigation in PAD
• Antitumor activity reported with TTFields in combination with gemcitabine and nab paclitaxel as first-line treatment for unresectable, locally advanced PAD
• Recent FDA approval of TTFields for locally advanced PAD; integration into clinical algorithms
• Ongoing evaluation of TTFields in combination with atezolizumab, gemcitabine and nab paclitaxel as first-line treatment for metastatic PAD

MODULE 8: Tolerability and Other Practical Considerations with TTFields

• Components of the TTFields system; placement of arrays for patients with PAD
• Appropriate skin preparation prior to array placement and during array changes with TTFields
• Spectrum, incidence and severity of dermatologic AEs documented with TTFields; appropriate mitigation and management strategies
• Other practical considerations associated with TTFields use, such as appropriate duration of treatment per day, bathing procedures and ability to travel

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of pancreatic cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Appreciate the biological, clinical and logistical factors that affect the selection of first-line therapy for locally advanced or metastatic pancreatic adenocarcinoma (PAD), and incorporate this information into patient education discussions.
• Assess published efficacy findings with regimens incorporating novel chemotherapeutic formulations as first-line therapy for patients with metastatic PAD, and understand the current role of these approaches.
• Examine available datasets exploring the effect of dose adjustments on the efficacy of chemotherapeutic regimens employed in the management of newly diagnosed metastatic PAD, and consider the potential feasibility of tolerability-guided dosing strategies.
• Recognize FDA-approved treatment approaches for metastatic PAD that has progressed on front-line chemotherapy, and counsel patients regarding the risks and benefits of these strategies.
• Evaluate the mechanism of action of, published research findings with and potential clinical role of tumor treating fields for unresectable, locally advanced PAD.
• Recall relevant oncogenic pathways mediating the pathogenesis of PAD, and discern the implications for biomarker analysis and treatment decision-making.
• Appreciate the spectrum and frequency of RAS mutations found in patients with metastatic PAD, and develop an understanding of available data with and ongoing research studies of novel agents designed to exploit this emerging therapeutic pathway.
• Design and implement a plan of care to recognize and manage side effects and toxicities associated with approved systemic regimens commonly employed in the management of PAD, to support quality of life and continuation of therapy.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/PancreaticCancer/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

FACULTY — Ms Kuhlman and Ms Wagner have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Philip — Advisory Committees: Corcept Therapeutics Inc, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Novocure Inc, Revolution Medicines Inc; Consulting Agreements: Novocure Inc; Contracted Research: Bristol Myers Squibb, Novartis, Revolution Medicines Inc, Taiho Oncology Inc; Data and Safety Monitoring Board/Committees: J-Pharma Co Ltd, Oncolytics Biotech Inc.

MODERATOR — Dr O’Reilly — Advisory Committees and Consulting Agreements (Uncompensated): Agenus Inc, Alligator Bioscience, Amgen Inc, Arcus Biosciences, Astellas, AstraZeneca Pharmaceuticals LP, BioNTech SE, Bristol Myers Squibb, Ikena Oncology, Immuneering Corporation, Ipsen Biopharmaceuticals Inc, Merck, MOMA Therapeutics, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Tango Therapeutics; Contracted Research: Agenus Inc, Amgen Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BioNTech SE, Digestive Care Inc, Elicio Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, Revolution Medicines Inc, Tango Therapeutics; Nonrelevant Financial Relationships: American Association of Cancer Research (Editor), American Society of Clinical Oncology (Editor), Break Through Cancer, Imedex, National Cancer Institute (Cancer Center Support Grant/Core Grant), National Institutes of Health (research grant), Stand Up 2 Cancer.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Ipsen Biopharmaceuticals Inc and Revolution Medicines Inc.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.